Skip to main content

MoneyWorks4Me

USFDA completes inspection at Natco Pharma’s formulation facility in Hyderabad

21 Nov 2026 Evaluate

The U.S. Food and Drug Administration (USFDA) has completed an inspection at Natco Pharma’s formulation manufacturing facility located in Kothur, Hyderabad, India. USFDA has conducted inspection from November 12 to November 20, 2026. Upon conclusion of the inspection, the company received seven observations in the Form-483. The observations are procedural in nature.

NATCO Pharma develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharma ingredients and crop protection products.

Peers
Company Name CMP
Sun Pharma. Inds. 1885.10
Dr. Reddys Labs. 1390.50
Cipla 1414.95
Lupin 2010.00
Zydus Lifesciences 1195.05
View more..